In-depth valuation analysis including DCF scenarios and peer comparisons.
AI Insight: Medtronic’s current price shows a 19% implied upside versus PERT-weighted fair value, indicating undervaluation with high confidence. Monte Carlo analysis reveals extreme volatility and a 34.3% downside risk below the current price, reflecting significant uncertainty. Financial health is good with strong liquidity, moderate profitability, and leverage, supporting stability amidst valuation variability.